(Q36838003)

16 August 2017

1 reference

title

A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data (English)

1 reference

16 August 2017

main subject

phase III clinical trial

0 references

author name string

Johnson KP

series ordinal

1

1 reference

16 August 2017

publication date

1 April 1996

1 reference

16 August 2017

1 reference

16 August 2017

volume

243

1 reference

16 August 2017

issue

4 Suppl 1

1 reference

16 August 2017

page(s)

S3-7

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00873695

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00873695

Multiple sclerosis: trial of a synthetic polypeptide

21 January 2018

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

1 reference

12 December 2020

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

12 December 2020

Experimental allergic encephalomyelitis--susceptibility and suppression

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

A new scale for evaluating disability in multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873695

1 reference

16 August 2017

1 reference